Market closedNon-fractional
Liquidia/LQDA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Liquidia
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Ticker
LQDA
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Morrisville, United States
Employees
145
Website
www.liquidia.com
Liquidia Metrics
BasicAdvanced
$876M
Market cap
-
P/E ratio
-$1.59
EPS
0.25
Beta
-
Dividend rate
Price and volume
Market cap
$876M
Beta
0.25
Financial strength
Current ratio
7.66
Quick ratio
7.317
Long term debt to equity
95.318
Total debt to equity
101.54
Interest coverage (TTM)
-12.11%
Management effectiveness
Return on assets (TTM)
-35.64%
Return on equity (TTM)
-128.27%
Valuation
Price to revenue (TTM)
48.575
Price to book
10.19
Price to tangible book (TTM)
11.13
Price to free cash flow (TTM)
-11.156
Growth
Revenue change (TTM)
-5.72%
Earnings per share change (TTM)
176.98%
3-year revenue growth (CAGR)
61.03%
3-year earnings per share growth (CAGR)
3.46%
What the Analysts think about Liquidia
Analyst Ratings
Majority rating from 7 analysts.
Liquidia Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$2.9M
-35.56%
Net income
-$41M
49.27%
Profit margin
-1,410.34%
131.63%
Liquidia Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.36
-$0.24
-$0.42
-$0.54
-
Expected
-$0.16
-$0.21
-$0.24
-$0.32
-$0.34
Surprise
120.47%
12.07%
78.61%
69.99%
-
Liquidia News
AllArticlesVideos
Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)
GlobeNewsWire·1 month ago
Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewsWire·2 months ago
Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Liquidia stock?
Liquidia (LQDA) has a market cap of $876M as of July 27, 2024.
What is the P/E ratio for Liquidia stock?
The price to earnings (P/E) ratio for Liquidia (LQDA) stock is 0 as of July 27, 2024.
Does Liquidia stock pay dividends?
No, Liquidia (LQDA) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Liquidia dividend payment date?
Liquidia (LQDA) stock does not pay dividends to its shareholders.
What is the beta indicator for Liquidia?
Liquidia (LQDA) has a beta rating of 0.25. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Liquidia stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.